Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation

Trends in Immunology

Volumn 32, Issue 4, 2011, Pages 157-164

  Krysko, Dmitri V ^a,b   Agostinis, Patrizia ^c   Krysko, Olga ^d   Garg, Abhishek D ^c   Bachert, Claus ^d   Lambrecht, Bart N ^d   Vandenabeele, Peter ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBAMOYL PHOSPHATE SYNTHASE; CYTOCHROME C; HIGH MOBILITY GROUP B1 PROTEIN; REACTIVE OXYGEN METABOLITE;

CELL DEATH; CELL FUNCTION; CELL MEMBRANE; CELL NUCLEUS; CYTOSOL; DAMAGE ASSOCIATED MOLECULAR PATTERN; ENDOPLASMIC RETICULUM; EXTRACELLULAR SPACE; HUMAN; IMMUNOMODULATION; INFLAMMATION; INJURY; MITOCHONDRION; NECROSIS; NONHUMAN; REVIEW;

ANIMALS; APOPTOSIS; HUMANS; INFLAMMATION; MITOCHONDRIA; NECROSIS; REACTIVE OXYGEN SPECIES;

EID: 79953068336     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2011.01.005     Document Type: Review

References (95)

1. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
2. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4:469-478.
3. Zitvogel L., et al. Decoding cell death signals in inflammation and immunity. Cell 2010, 140:798-804.
4. Scheibner K.A., et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 2006, 177:1272-1281.
5. Garg A.D., et al. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim. Biophys. Acta 2010, 1805:53-71.
6. Saito H., et al. Extracellular ATP stimulates interleukin-dependent cultured mast cells and eosinophils through calcium mobilization. Int. Arch. Allergy Appl. Immunol. 1991, 94:68-70.
7. Lotfi R., et al. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J. Immunother. 2007, 30:16-28.
8. Kobayashi T., et al. Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP. J. Immunol. 2010, 184:6350-6358.
9. Zhang Q., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.
10. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 2009, 227:221-233.
11. Rubartelli A., Lotze M.T. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007, 28:429-436.
12. Krysko D.V., et al. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006, 11:1709-1726.
13. Bondanza A., et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J. Exp. Med. 2004, 200:1157-1165.
14. Franc N.C., et al. Phagocytosis and development: back to the future. Curr. Opin. Immunol. 1999, 11:47-52.
15. Obeid M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
16. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
17. Gray M.W., et al. Mitochondrial evolution. Science 1999, 283:1476-1481.
18. Zimmer C. Origins. On the origin of eukaryotes. Science 2009, 325:666-668.
19. Bone R.C., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655.
20. Muckart D.J., Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit. Care Med. 1997, 25:1789-1795.
21. Xiang M., Fan J. Pattern recognition receptor-dependent mechanisms of acute lung injury. Mol. Med. 2010, 16:69-82.
22. Cohen M.J., et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit. Care 2009, 13:R174.
23. Kleindienst A., et al. The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog. Brain Res. 2007, 161:317-325.
24. Zhang Q., et al. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock 2010, 34:55-59.
25. Collins L.V., et al. Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J. Leukoc. Biol. 2004, 75:995-1000.
26. von Kockritz-Blickwede M., Nizet V. Innate immunity turned inside-out: antimicrobial defense by phagocyte extracellular traps. J. Mol. Med. 2009, 87:775-783.
27. Yousefi S., et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat. Med. 2008, 14:949-953.
28. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J. Exp. Med. 1982, 155:264-275.
29. Migeotte I., et al. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 2006, 17:501-519.
30. Ye R.D., et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 2009, 61:119-161.
31. Boulay F., et al. The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry 1990, 29:11123-11133.
32. Gavins F.N. Are formyl peptide receptors novel targets for therapeutic intervention in ischaemia-reperfusion injury?. Trends Pharmacol. Sci. 2010, 31:266-276.
33. Shawar S.M., et al. Peptides from the amino-terminus of mouse mitochondrially encoded NADH dehydrogenase subunit 1 are potent chemoattractants. Biochem. Biophys. Res. Commun. 1995, 211:812-818.
34. Rabiet M.J., et al. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur. J. Immunol. 2005, 35:2486-2495.
35. Raoof M., et al. Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. J. Trauma 2010, 68:1328-1334.
36. Czapiga M., et al. Human platelets exhibit chemotaxis using functional N-formyl peptide receptors. Exp. Hematol. 2005, 33:73-84.
37. McDonald B., et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330:362-366.
38. Crouser E.D., et al. Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors. Crit. Care Med. 2009, 37:2000-2009.
39. Wang Y., Bogenhagen D.F. Human mitochondrial DNA nucleoids are linked to protein folding machinery and metabolic enzymes at the mitochondrial inner membrane. J. Biol. Chem. 2006, 281:25791-25802.
40. Parisi M.A., Clayton D.A. Similarity of human mitochondrial transcription factor 1 to high mobility group proteins. Science 1991, 252:965-969.
41. Riedl S.J., Salvesen G.S. The apoptosome: signalling platform of cell death. Nat. Rev. Mol. Cell Biol. 2007, 8:405-413.
42. Orrenius S., et al. Mitochondrial oxidative stress: implications for cell death. Annu. Rev. Pharmacol. Toxicol. 2007, 47:143-183.
43. Denecker G., et al. Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria. Cell Death Differ. 2001, 8:829-840.
44. Jemmerson R., et al. Release of intact, monomeric cytochrome c from apoptotic and necrotic cells. Cell Death Differ. 2002, 9:538-548.
45. Renz A., et al. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood 2001, 98:1542-1548.
46. Kruse K., et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010, 15:1098-1113.
47. Mamula M.J., et al. The specificity of human anti-cytochrome c autoantibodies that arise in autoimmune disease. J. Immunol. 1990, 144:1835-1840.
48. Miller T.J., et al. Cytochrome c: a non-invasive biomarker of drug-induced liver injury. J. Appl. Toxicol. 2008, 28:815-828.
49. Adachi N., et al. Serum cytochrome c level as a prognostic indicator in patients with systemic inflammatory response syndrome. Clin. Chim. Acta 2004, 342:127-136.
50. Radhakrishnan J., et al. Circulating levels of cytochrome c after resuscitation from cardiac arrest: a marker of mitochondrial injury and predictor of survival. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H767-775.
51. Nunoi H., et al. Apoptosis under hypercytokinemia is a possible pathogenesis in influenza-associated encephalopathy. Pediatr. Int. 2005, 47:175-179.
52. Barczyk K., et al. Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int. J. Cancer 2005, 116:167-173.
53. Pullerits R., et al. Extracellular cytochrome c, a mitochondrial apoptosis-related protein, induces arthritis. Rheumatology (Oxford) 2005, 44:32-39.
54. Codina R., et al. Cytochrome c-induced lymphocyte death from the outside in: inhibition by serum leucine-rich alpha-2-glycoprotein-1. Apoptosis 2010, 15:139-152.
55. Paradies G., et al. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J. Pineal Res. 2010, 48:297-310.
56. Deli T., Csernoch L. Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors. Pathol. Oncol. Res. 2008, 14:219-231.
57. Stagg J., Smyth M.J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010, 29:5346-5358.
58. Ghiringhelli F., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009, 15:1170-1178.
59. Elliott M.R., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461:282-286.
60. Chekeni F.B., et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 2010, 467:863-867.
61. De Angelis A., et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2009, 121:276-292.
62. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
63. Iyer S.S., et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20388-20393.
64. Ott M., et al. Mitochondria, oxidative stress and cell death. Apoptosis 2007, 12:913-922.
65. Ricci J.E., et al. Caspase-mediated loss of mitochondrial function and generation of reactive oxygen species during apoptosis. J. Cell Biol. 2003, 160:65-75.
66. Ricci J.E., et al. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 2004, 117:773-786.
67. Kazama H., et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008, 29:21-32.
68. Zhou R., et al. A role for mitochondria in NLRP3 inflammasome activation. Nature 2010, 469:221-225.
69. Schug Z.T., Gottlieb E. Cardiolipin acts as a mitochondrial signalling platform to launch apoptosis. Biochim. Biophys. Acta 2009, 1788:2022-2031.
70. Schlame M. Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. J. Lipid Res. 2008, 49:1607-1620.
71. Epand R.M., Epand R.F. Lipid domains in bacterial membranes and the action of antimicrobial agents. Biochim. Biophys. Acta 2009, 1788:289-294.
72. Garcia Fernandez M., et al. Early changes in intramitochondrial cardiolipin distribution during apoptosis. Cell Growth Differ. 2002, 13:449-455.
73. Sorice M., et al. Cardiolipin and its metabolites move from mitochondria to other cellular membranes during death receptor-mediated apoptosis. Cell Death Differ. 2004, 11:1133-1145.
74. Valesini G., Alessandri C. New facet of antiphospholipid antibodies. Ann. N. Y. Acad. Sci. 2005, 1051:487-497.
75. Struck J., et al. Release of the mitochondrial enzyme carbamoyl phosphate synthase under septic conditions. Shock 2005, 23:533-538.
76. Jones D.E. Autoantigens in primary biliary cirrhosis. J. Clin. Pathol. 2000, 53:813-821.
77. Kroemer G., et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16:3-11.
78. Duprez L., et al. Major cell death pathways at a glance. Microbes Infect. 2009, 11:1050-1062.
79. Saelens X., et al. Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23:2861-2874.
80. Vanlangenakker N., et al. Molecular mechanisms and pathophysiology of necrotic cell death. Curr. Mol. Med. 2008, 8:207-220.
81. Degterev A., et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 2005, 1:112-119.
82. Vandenabeele P., et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 2010, 11:700-714.
83. Klune J.R., et al. HMGB1: endogenous danger signaling. Mol. Med. 2008, 14:476-484.
84. Ronfani L., et al. Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein Hmgb2. Development 2001, 128:1265-1273.
85. Scaffidi P., et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
86. Thorburn J., et al. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ. 2009, 16:175-183.
87. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007, 81:1-5.
88. Rouhiainen A., et al. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J. Leukoc. Biol. 2007, 81:49-58.
89. Bianchi M.E. HMGB1 loves company. J. Leukoc. Biol. 2009, 86:573-576.
90. Branco-Madeira F., Lambrecht B.N. High mobility group box-1 recognition: the beginning of a RAGEless era?. EMBO Mol. Med. 2010, 2:193-195.
91. Yanai H., et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462:99-103.
92. Chen G.Y., et al. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009, 323:1722-1725.
93. Krysko D.V., et al. Methods for distinguishing apoptotic from necrotic cells and measuring their clearance. Methods Enzymol. 2008, 442:307-341.
94. Rabiet M.J., et al. The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie 2007, 89:1089-1106.
95. Martins I., et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009, 8:3723-3728.